Literature DB >> 24521531

Can we build an efficient response to the prescription drug abuse epidemic? Assessing the cost effectiveness of universal prevention in the PROSPER trial.

D Max Crowley1, Damon E Jones2, Donna L Coffman3, Mark T Greenberg2.   

Abstract

PURPOSE: Prescription drug abuse has reached epidemic proportions. Nonmedical prescription opioid use carries increasingly high costs. Despite the need to cultivate efforts that are both effective and fiscally responsible, the cost-effectiveness of universal evidence-based-preventive-interventions (EBPIs) is rarely evaluated. This study explores the performance of these programs to reduce nonmedical prescription opioid use.
METHODS: Sixth graders from twenty-eight rural public school districts in Iowa and Pennsylvania were blocked by size and geographic location and then randomly assigned to experimental or control conditions (2002-2010). Within the intervention communities, prevention teams selected a universal family and school program from a menu of EBPIs. All families were offered a family-based program in the 6th grade and received one of three school-based programs in 7th-grade. The effectiveness and cost-effectiveness of each school program by itself and with an additional family-based program were assessed using propensity and marginal structural models.
RESULTS: This work demonstrates that universal school-based EBPIs can efficiently reduce nonmedical prescription opioid use. Further, findings illustrate that family-based programs may be used to enhance the cost-effectiveness of school-based programs.
CONCLUSIONS: Universal EBPIs can effectively and efficiently reduce nonmedical prescription opioid use. These programs should be further considered when developing comprehensive responses to this growing national crisis.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cost-effectiveness; Nonmedical prescription drug use; Prevention economics; Substance abuse; Universal prevention

Mesh:

Year:  2014        PMID: 24521531      PMCID: PMC4131945          DOI: 10.1016/j.ypmed.2014.01.029

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  39 in total

Review 1.  Prescription drug abuse: insight into the epidemic.

Authors:  S H Hernandez; L S Nelson
Journal:  Clin Pharmacol Ther       Date:  2010-08-04       Impact factor: 6.875

2.  The prescription drug epidemic in the United States: a perfect storm.

Authors:  Jane Carlisle Maxwell
Journal:  Drug Alcohol Rev       Date:  2011-05

Review 3.  Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation.

Authors:  A H Briggs; D E Wonderling; C Z Mooney
Journal:  Health Econ       Date:  1997 Jul-Aug       Impact factor: 3.046

4.  Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial.

Authors:  Daniel Polsky; Henry A Glick; Jianing Yang; Geetha A Subramaniam; Sabrina A Poole; George E Woody
Journal:  Addiction       Date:  2010-07-12       Impact factor: 6.526

5.  Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.

Authors:  Bruce R Schackman; Jared A Leff; Daniel Polsky; Brent A Moore; David A Fiellin
Journal:  J Gen Intern Med       Date:  2012-01-04       Impact factor: 5.128

6.  Economic analysis of methamphetamine prevention effects and employer costs.

Authors:  Max Guyll; Richard Spoth; D Max Crowley
Journal:  J Stud Alcohol Drugs       Date:  2011-07       Impact factor: 2.582

Review 7.  Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.

Authors:  M Connock; A Juarez-Garcia; S Jowett; E Frew; Z Liu; R J Taylor; A Fry-Smith; E Day; N Lintzeris; T Roberts; A Burls; R S Taylor
Journal:  Health Technol Assess       Date:  2007-03       Impact factor: 4.014

Review 8.  Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood: implications for substance abuse prevention.

Authors:  J D Hawkins; R F Catalano; J Y Miller
Journal:  Psychol Bull       Date:  1992-07       Impact factor: 17.737

Review 9.  Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids.

Authors:  Laxmaiah Manchikanti; Angelie Singh
Journal:  Pain Physician       Date:  2008-03       Impact factor: 4.965

10.  Motives for nonmedical use of prescription opioids among high school seniors in the United States: self-treatment and beyond.

Authors:  Sean Esteban McCabe; Carol J Boyd; James A Cranford; Christian J Teter
Journal:  Arch Pediatr Adolesc Med       Date:  2009-08
View more
  15 in total

1.  Targeting Youth to Prevent Later Substance Use Disorder: An Underutilized Response to the US Opioid Crisis.

Authors:  Wilson M Compton; Christopher M Jones; Grant T Baldwin; Frances M Harding; Carlos Blanco; Eric M Wargo
Journal:  Am J Public Health       Date:  2019-06       Impact factor: 9.308

2.  A National Cost Analysis of Community Interventions to Prevent Underage Drinking and Prescription Drug Misuse.

Authors:  Carolina Close; Elvira Elek; Cheryl A Roberts; Laura J Dunlap; Phillip W Graham; Nichole M Scaglione; Lori-Ann Palen; Thomas Clarke
Journal:  Prev Sci       Date:  2021-05-28

3.  Prescription tranquilizer/sedative misuse prevalence and correlates across age cohorts in the US.

Authors:  Ty S Schepis; Christian J Teter; Linda Simoni-Wastila; Sean Esteban McCabe
Journal:  Addict Behav       Date:  2018-06-12       Impact factor: 3.913

Review 4.  Financing prevention: opportunities for economic analysis across the translational research cycle.

Authors:  D Max Crowley; Damon Jones
Journal:  Transl Behav Med       Date:  2016-03       Impact factor: 3.046

5.  Translating Prevention Research for Evidence-Based Policymaking: Results from the Research-to-Policy Collaboration Pilot.

Authors:  Max Crowley; J Taylor Bishop Scott; Diana Fishbein
Journal:  Prev Sci       Date:  2018-02

6.  Age of initiation, psychopathology, and other substance use are associated with time to use disorder diagnosis in persons using opioids nonmedically.

Authors:  Ty S Schepis; Jahn K Hakes
Journal:  Subst Abus       Date:  2017-07-19       Impact factor: 3.716

7.  Understanding the increase in opioid overdoses in New Hampshire: A rapid epidemiologic assessment.

Authors:  Andrea Meier; Sarah K Moore; Elizabeth C Saunders; Bethany McLeman; Stephen A Metcalf; Samantha Auty; Olivia Walsh; Lisa A Marsch
Journal:  Drug Alcohol Depend       Date:  2020-02-07       Impact factor: 4.492

8.  Prevalence and correlates of co-ingestion of prescription tranquilizers and other psychoactive substances by U.S. high school seniors: Results from a national survey.

Authors:  Ty S Schepis; Brady T West; Christian J Teter; Sean Esteban McCabe
Journal:  Addict Behav       Date:  2015-08-12       Impact factor: 3.913

9.  Valuing Our Communities: Ethical Considerations for Economic Evaluation of Community-Based Prevention.

Authors:  Max Crowley; Damon Jones
Journal:  Am J Community Psychol       Date:  2017-11-20

Review 10.  Guidelines for Opioid Prescribing in Children and Adolescents After Surgery: An Expert Panel Opinion.

Authors:  Lorraine I Kelley-Quon; Matthew G Kirkpatrick; Robert L Ricca; Robert Baird; Calista M Harbaugh; Ashley Brady; Paula Garrett; Hale Wills; Jonathan Argo; Karen A Diefenbach; Marion C W Henry; Juan E Sola; Elaa M Mahdi; Adam B Goldin; Shawn D St Peter; Cynthia D Downard; Kenneth S Azarow; Tracy Shields; Eugene Kim
Journal:  JAMA Surg       Date:  2021-01-01       Impact factor: 14.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.